Promising results from Phase II clinical trial

American association cancer research We were encouraged to see some very promising results from a Phase II clinical trial for high grade Neuroendocrine Carcinoma (NEC) patients, using a combination of Immunotherapy drugs. The results of this trial were recently presented at the American Association for Cancer Research Annual Meeting.

Click here for link to full press release

We welcome more research for these NEC patients and all NET Cancer patients and look forward to seeing more results based on real world experience.

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

NECA Joins Boehringer Ingelheim Panel Discussion on Clinical Trials and Patient Access

Read article

Expressions of interest open for ANZSNM nurse and allied health workshop in Canberra

Read article

NECA partners with Oncidium ahead of World Radiotheranostics Day 2026

Read article

Bringing Together Experts to Improve NET Patient Care: NECA at the 5th NET Preceptorship

Read article

Quick Links

Newly Diagnosed
Living with NETs
Optimal Care Pathway
Close

Tax Appeal

Screenshot 2026-05-20 at 2.12.07 PM

Help 31,000+ neuroendocrine cancer patients get the specialised care they deserve.

Every dollar raised is fully tax deductible and helps fund much needed advocacy efforts and patient support.

Donate before 30 June